Effect of mepyramine and spasmolytic agents on guinea-pig anaphylaxis with special reference to the protracted shock.
D000707:Anaphylaxis / Q000188:drug therapy* / Q000209:etiology; D000818:Animals; D000941:Antigens; D001593:Benzyl Compounds / Q000627:therapeutic use; D001966:Bromine / Q000627:therapeutic use; D004149:Dioxoles / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005021:Ethylamines / Q000627:therapeutic use; D005029:Ethylenediamines / Q000627:therapeutic use; D005260:Female; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D007783:Lactones / Q000627:therapeutic use; D008297:Male; D010047:Ovalbumin; D010208:Papaverine / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D011810:Quinoxalines / Q000627:therapeutic use; D012601:Scopolamine / Q000627:therapeutic use; D013343:Styrenes / Q000627:therapeutic use
D000941:Antigens; D001593:Benzyl Compounds; D004149:Dioxoles; D005021:Ethylamines; D005029:Ethylenediamines; D006634:Histamine H1 Antagonists; D007783:Lactones; D010276:Parasympatholytics; D011725:Pyridines; D011810:Quinoxalines; D013343:Styrenes; D010047:Ovalbumin; D010208:Papaverine; D012601:Scopolamine; D001966:Bromine